As part of CRA’s issues leadership initiative to challenge industry thinking on rare diseases, we assembled a panel of CRA experts to discuss the opportunities and challenges posed by the latest therapeutic breakthroughs in conditions that affect fewer than one in 2,000 people. Neil Turner moderates a discussion with Greg Bell, Kevin Brubacher, Ned Kitfield, Cécile Matthews, and Tim Wilsdon.
Funding innovation under pressure: examining the role of commercial health insurance in Europe
Europe’s health systems are facing growing pressure amidst strained public budgets, ageing populations, and increasing treatment costs, prompting urgent questio